查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930120

全球带状疱疹疫苗市场：市场规模、占有率、成长率、行业分析、依类型、应用和地区划分的考察、未来预测（2026-2034）

Shingles Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

带状疱疹疫苗市场成长因素

受疾病流行率上升、人口老化以及成人预防性免疫意识增强的推动，全球带状疱疹疫苗市场在2025年基准年呈现显着成长。报告显示，2025年市场规模为56.7亿美元。在先进疫苗不断推出和疫苗接种覆盖范围扩大的推动下，预计2026年市场规模将成长至59.5亿美元，到2034年将进一步成长至129.2亿美元。北美地区凭藉着较高的市场意识、完善的医疗保健基础设施以及重组带状疱疹疫苗的广泛应用，在2025年占据全球市场36.98%的市场占有率。

带状疱疹疫苗用于预防带状疱疹，这是一种由水痘-带状疱疹病毒再活化引起的疼痛且常导致残疾的疾病。该病毒在人类感染水痘后可能处于潜伏状态，并在日后再次活化，尤其是在老年人和免疫功能低下的人群中。接种疫苗（需接种两剂）仍然是预防带状疱疹及其併发症的唯一有效方法。

市场动态

市场驱动因素

2025年至2026年，全球带状疱疹发生率的上升是推动市场成长的主要因素。老化和免疫老化会显着增加对带状疱疹的敏感性，导致对疫苗的需求增加。根据2023年9月发布的资料，年轻健康成年人中带状疱疹的发生率在每年每千人1.2至3.4例之间，老年人群的发生率更高。同时，公众意识的提高和卫生部门的建议进一步促进了疫苗接种。

市场限制因子

带状疱疹疫苗的副作用仍然是一个限制因素。不良反应，例如注射部位疼痛、疲劳、发烧和罕见的神经系统症状，会影响患者的信心。2023年，加拿大因安全问题暂停了Zostavax的销售，这凸显了耐受性问题如何影响市场动态，并引发对更安全替代方案的需求转变。

市场机会

解决成本障碍是关键的成长机会。高昂的疫苗价格和有限的保险覆盖范围阻碍了疫苗在一些地区的广泛应用。截至2025年2月，印度两剂SHINGRIX疫苗的价格在300至400美元之间，限制了疫苗的普及。降价、政府补贴和扩大偿付范围预计在2034年之前促进市场成长，并显着提高疫苗接种率。

市场挑战

某些地区疫苗认知度低和接种管道有限，对市场扩张构成挑战。根据2023年10月发布的一项研究，57.2%的目标族群了解带状疱疹疫苗，但接种率仅7.7%。认知度和接种管道的差异对实现最佳疫苗覆盖率构成挑战。

带状疱疹疫苗市场趋势

影响全球市场的关键趋势是重组次单位疫苗的日益普及。像SHINGRIX这样的非活性疫苗因其卓越的疗效和安全性，尤其是在老年人和免疫功能低下人群中，正成为更受欢迎的选择。2024年7月发表的临床资料证实，重组疫苗不仅能预防带状疱疹，还能显着降低带状疱疹后神经痛的风险，进一步巩固了其市场地位。

市场区隔分析

依类型

重组/结合/次单位疫苗在2024年占据市场主导地位，并在2034年之前保持最快的成长速度。这些疫苗在提供高保护率的同时，也避免了减毒活疫苗的相关风险。 "其他" 疫苗类别，包括基于mRNA的疫苗，也正受到越来越多的关注，目前已有多个候选疫苗进入临床试验阶段。

依产品

2024年，SHINGRIX疫苗凭藉其强大的临床疗效，占据了最大的市场占有率。2024年7月发布的资料显示，SHINGRIX疫苗在预防50-69岁成年人带状疱疹方面的有效率高达97%，巩固了其领先地位。该细分市场的剩余部分由在研产品构成，包括基于mRNA的疫苗。

依通路划分

在国家疫苗接种计划和优惠的偿付政策的推动下，政府机构在2024年占据了市场主导地位。由于公私合作的增加以及城市医疗保健服务可近性的提高，医院和零售药局预计将继续占据相当大的市场占有率。

区域展望

北美

在疾病高发生率且强有力的疫苗接种计画的推动下，北美市场在2025年达到21亿美元，预计在2026年达到21.6亿美元。美国每年约有100万例带状疱疹病例，在该地区位居榜首，支撑着持续的疫苗需求。

欧洲

欧洲拥有第二大市场占有率，这得益于有利的偿付机制和区域性的宣传活动。欧盟各国的合作活动提高成人疫苗接种率。

亚太地区

亚太地区是成长最快的地区，这主要得益于人口老化、可支配收入增加以及政府主导的疫苗接种活动的扩大。主要生产商所进行的宣传活动也推动市场成长。

拉丁美洲、中东和非洲

由于医疗保健服务的改善、公众意识的提高以及先进带状疱疹疫苗的逐步推广，预计这些地区的市场将保持稳定成长。

带状疱疹疫苗市场报告对2025年、2026年和2034年的市场价值进行了严格的预测，并提供了全面的分析。报告涵盖了市场动态、依类型、产品和通路划分的市场细分、区域表现、竞争格局和关键发展，对预测期内的市场演变提供了详细的分析。

展望未来，预计到2034年，带状疱疹疫苗市场规模将达到129.2亿美元。这一成长主要得益于人口老化带来的持续需求、非活性疫苗平台的技术进步以及包括基于mRNA的带状疱疹疫苗在内的在研产品线。儘管在某些地区，成本障碍、副作用和区域认知度不均仍然是挑战，但政府支持的增加、偿付政策的完善以及公私合作的推进有望提高疫苗的可及性和普及率。总体而言，带状疱疹疫苗市场预计将在预测期内保持长期稳定的价值成长，继续在成人免疫和医疗保健领域发挥重要作用。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 带状疱疹（疱疹病毒感染）的流行病学
  • 主要国家的偿付情况
  • 主要公司的产品线分析
  • 主要公司的新产品发布
  • 关键产业趋势：併购、业务合作等

章节5 全球带状疱疹疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型
    • 重组/结合/次单位疫苗
    • 其他
  • 市场分析、洞察与预测：依产品
    • SHINGRIX
    • 其他
  • 市场分析、洞察与预测：依销售管道
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测：依地区
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美带状疱疹疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲带状疱疹疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第8章 亚太地区带状疱疹疫苗市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 亚太其他地区

第9章 拉丁美洲带状疱疹疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第10章 中东与非洲带状疱疹疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • GCC国家
    • 南非
    • 中东其他地区非洲

第11章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
    • GSK plc
    • Moderna Inc.
    • Jiangsu Recbio Technology Co., Ltd.
    • Pfizer Inc.
    • Dynavax Technologies
    • Curevo Inc.
Product Code: FBI102072

Growth Factors of Shingles Vaccines Market

The global Shingles Vaccines Market demonstrated strong expansion in the base year 2025, driven by rising disease prevalence, increasing geriatric population, and growing awareness regarding preventive adult immunization. According to the report, the market size was valued at USD 5.67 billion in 2025. With continued uptake of advanced vaccines and broader immunization coverage, the market is projected to grow to USD 5.95 billion in 2026 and further expand to USD 12.92 billion by 2034. North America dominated the global landscape with a 36.98% market share in 2025, supported by high awareness levels, strong healthcare infrastructure, and widespread adoption of recombinant shingles vaccines.

Shingles vaccines are used to prevent herpes zoster, a painful and often debilitating condition caused by reactivation of the varicella-zoster virus. The virus remains dormant after an individual recovers from chickenpox and can reactivate later in life, particularly among older adults and immunocompromised populations. Vaccination, administered in a two-dose schedule, remains the only effective preventive measure against shingles and its complications.

Market Dynamics

Market Drivers

The rising incidence of shingles globally is a primary factor driving market growth across 2025 and 2026. Aging populations and immunosenescence significantly increase susceptibility to shingles, resulting in higher vaccine demand. Data published in September 2023 indicated a shingles prevalence rate of 1.2-3.4 cases per 1,000 persons per year among younger healthy adults, with substantially higher rates in older populations. In parallel, increasing awareness campaigns and recommendations from health authorities further boost vaccine adoption.

Market Restraints

Side effects associated with shingles vaccines remain a limiting factor. Adverse reactions such as injection-site pain, fatigue, fever, and rare neurological conditions can affect patient confidence. In 2023, Canada discontinued Zostavax due to safety concerns, highlighting how tolerability issues can influence market dynamics and shift demand toward safer alternatives.

Market Opportunities

Addressing cost barriers represents a major growth opportunity. High vaccine prices and limited insurance coverage restrict uptake in several regions. In February 2025, the cost of two doses of SHINGRIX in India ranged between USD 300-400, limiting accessibility. Price reductions, government subsidies, and reimbursement expansion could significantly improve adoption rates and support market growth toward 2034.

Market Challenges

Limited awareness and restricted access in certain regions challenge market expansion. Studies published in October 2023 showed that while 57.2% of participants were aware of the shingles vaccine in selected populations, only 7.7% had received it. Such gaps in awareness and access continue to hinder optimal vaccine coverage.

Shingles Vaccines Market Trends

A key trend shaping the global market is the increasing adoption of recombinant subunit vaccines. Non-live vaccines such as SHINGRIX are preferred due to their superior efficacy and safety profile, particularly for older and immunocompromised individuals. In July 2024, clinical data confirmed that recombinant vaccines not only prevent shingles but also significantly reduce the risk of postherpetic neuralgia, reinforcing their growing dominance.

Segmentation Analysis

By Type

The recombinant/conjugate/subunit segment dominated the market in 2024 and is expected to register the fastest growth through 2034. These vaccines offer high protection without the risks associated with live attenuated formulations. The "others" segment, including mRNA-based vaccines, is gaining attention, with multiple candidates entering clinical trials.

By Product

The SHINGRIX segment held the largest market share in 2024, supported by strong clinical efficacy. Data published in July 2024 showed SHINGRIX to be 97% effective in preventing shingles among adults aged 50-69 years, reinforcing its leadership position. Pipeline products, including mRNA-based vaccines, form the remainder of the segment.

By Distribution Channel

Government suppliers dominated the market in 2024, driven by national immunization initiatives and favorable reimbursement policies. Hospital and retail pharmacies are expected to maintain significant shares due to increasing public-private partnerships and improved access in urban healthcare settings.

Regional Outlook

North America

North America generated USD 2.10 billion in 2025 and USD 2.16 billion in 2026, driven by high disease prevalence and strong vaccination programs. The U.S. leads the region, with approximately 1 million shingles cases annually, supporting sustained vaccine demand.

Europe

Europe holds the second-largest share, supported by favorable reimbursement frameworks and region-wide awareness initiatives. Collaborative campaigns have strengthened adult vaccination coverage across EU countries.

Asia Pacific

Asia Pacific is the fastest-growing region, supported by rising elderly populations, increasing disposable income, and expanding government-backed immunization efforts. Awareness campaigns by leading manufacturers further support growth.

Latin America and Middle East & Africa

These regions are expected to witness steady growth, driven by improving healthcare access, rising awareness, and gradual introduction of advanced shingles vaccines.

Competitive Landscape

The market is led by GSK plc. and Pfizer Inc., which together account for a significant share. GSK's SHINGRIX remains the most widely adopted product globally, supported by regulatory approvals and awareness initiatives. Pfizer, in collaboration with BioNTech, is advancing mRNA-based shingles vaccines. Other notable players include Moderna Inc., Dynavax Technologies, Jiangsu Recbio Technology Co., Ltd., and Curevo Inc., all actively investing in next-generation vaccine development.

Report Coverage

The shingles vaccines market report provides a comprehensive analysis aligned strictly with 2025, 2026, and 2034 market values. It covers market dynamics, segmentation by type, product, and distribution channel, regional performance, competitive landscape, and key industry developments, offering a detailed view of market evolution across the forecast period.

Conclusion

The global Shingles Vaccines Market exhibits a strong and well-supported growth outlook across the report years, driven by rising shingles incidence, demographic aging, and increasing emphasis on adult preventive immunization. Valued at USD 5.67 billion in 2025, the market reflects growing acceptance of vaccination as the most effective preventive strategy against herpes zoster and its long-term complications. The steady rise to USD 5.95 billion in 2026 highlights continued short-term expansion supported by awareness initiatives, strong government participation, and high adoption of recombinant subunit vaccines, particularly in North America, which accounted for 36.98% of the global market in 2025.

Looking ahead, the projected expansion to USD 12.92 billion by 2034 is underpinned by sustained demand from aging populations, technological advancements in non-live vaccine platforms, and pipeline developments such as mRNA-based shingles vaccines. While challenges related to cost barriers, side effects, and uneven awareness persist across certain regions, increasing government support, reimbursement policies, and public-private collaborations are expected to enhance accessibility and uptake. Overall, the shingles vaccines market is positioned for consistent long-term value growth, maintaining its critical role in adult immunization and preventive healthcare throughout the forecast period.

Segmentation

By Type

  • Recombinant/Conjugate/Subunit
  • Others

By Product

  • SHINGRIX
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Product, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Product, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Product, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • o
    • Rest of Asia Pacific
  • Latin America (By Type, Product, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Product, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Shingles (Herpes Zoster)
  • 4.2. Reimbursement Scenario, By Key Countries/Regions
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Recombinant/Conjugate/Subunit
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - Product
    • 5.2.1. SHINGRIX
    • 5.2.2. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital & Retail Pharmacies
    • 5.3.2. Government Suppliers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Recombinant/Conjugate/Subunit
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - Product
    • 6.2.1. SHINGRIX
    • 6.2.2. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital & Retail Pharmacies
    • 6.3.2. Government Suppliers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Recombinant/Conjugate/Subunit
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - Product
    • 7.2.1. SHINGRIX
    • 7.2.2. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital & Retail Pharmacies
    • 7.3.2. Government Suppliers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Recombinant/Conjugate/Subunit
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - Product
    • 8.2.1. SHINGRIX
    • 8.2.2. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital & Retail Pharmacies
    • 8.3.2. Government Suppliers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Recombinant/Conjugate/Subunit
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - Product
    • 9.2.1. SHINGRIX
    • 9.2.2. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital & Retail Pharmacies
    • 9.3.2. Government Suppliers
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Recombinant/Conjugate/Subunit
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - Product
    • 10.2.1. SHINGRIX
    • 10.2.2. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital & Retail Pharmacies
    • 10.3.2. Government Suppliers
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Moderna Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Jiangsu Recbio Technology Co., Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Pfizer Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Dynavax Technologies
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Curevo Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 3: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 6: North America Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 7: North America Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Shingles Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 10: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 11: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 13: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 15: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 17: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 19: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 21: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 23: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Shingles Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Shingles Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Shingles Vaccines Market Value Share (%), by Product, 2025 & 2034
  • Figure 4: Global Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Shingles Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Shingles Vaccines Market Value Share (%), by Type, 2025
  • Figure 8: North America Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 9: North America Shingles Vaccines Market Value Share (%), by Product, 2025
  • Figure 10: North America Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Shingles Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Shingles Vaccines Market Value Share (%), By Country, 2025
  • Figure 14: Europe Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Shingles Vaccines Market Value Share (%), by Type, 2025
  • Figure 16: Europe Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 17: Europe Shingles Vaccines Market Value Share (%), by Product, 2025
  • Figure 18: Europe Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 21: Europe Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 22: Asia Pacific Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Shingles Vaccines Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 25: Asia Pacific Shingles Vaccines Market Value Share (%), by Product, 2025
  • Figure 26: Asia Pacific Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 29: Asia Pacific Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 30: Latin America Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Latin America Shingles Vaccines Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 33: Latin America Shingles Vaccines Market Value Share (%), by Product, 2025
  • Figure 34: Latin America Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 37: Latin America Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 38: Middle East & Africa Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 39: Middle East & Africa Shingles Vaccines Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 41: Middle East & Africa Shingles Vaccines Market Value Share (%), by Product, 2025
  • Figure 42: Middle East & Africa Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 45: Middle East & Africa Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 46: Global Shingles Vaccines Market Share (%), By Company, 2025